Literature DB >> 29340728

Indocyanine Green Retention Rates at 15 min Predicted Hepatic Decompensation in a Western Population.

Bertrand Le Roy1,2, Emilie Grégoire3, Cyril Cossé4, Badr Serji4, Nicolas Golse4,5, René Adam4, Daniel Cherqui4, Jean-Yves Mabrut5, Yves-Patrice Le Treut3, Eric Vibert4.   

Abstract

BACKGROUND: ICGR15 is widely used in Asia to evaluate the liver reserve before hepatectomy, but not in Western countries where patients are selected using the MELD score and/or platelet count. Postoperative liver failure is rare nowadays, but hepatic decompensation (HD), defined by 3-month postoperative ascites, impairs quality of life and survival. The aim of this study was to evaluate the relevance of indocyanine green retention rate at 15 min (ICGR15) before liver resection in Western countries, in order to predict HD.
METHODS: This prospectively designed study included consecutive adult patients undergoing hepatectomy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) in three French HPB centres.
RESULTS: Between 2012 and 2014, 147 patients were included (80% of HCC and 20% of ICC). The Child-Pugh status was grade A for all patients. In the overall population and in F3/F4 patients (n = 83), ICGR15 (P = 0.02) and platelet counts (P = 0.02) were predictive of HD under multivariate analysis. Among F3/F4 patients undergoing minor hepatectomy with preoperative ICGR15 > 15%, the rate of HD was 36%. In the overall population, ICGR15 was predictive of HD (P = 0.02) and postoperative ascites (P = 0.03). The ROC curve identified a cut-off point of 15% as being associated with increased HD, with good accuracy for ICGR15 in the study population (AUROC 0.73), mainly before minor hepatectomy (AUROC 0.79).
CONCLUSIONS: In patients with HCC and ICC selected using the MELD score and platelet rate, an ICGR15 > 15% is a relevant, non-invasive and clearly accurate method to predict HD specially before minor hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29340728     DOI: 10.1007/s00268-018-4464-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  31 in total

1.  Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy.

Authors:  H Lau; K Man; S T Fan; W C Yu; C M Lo; J Wong
Journal:  Br J Surg       Date:  1997-09       Impact factor: 6.939

2.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

3.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

Review 4.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

Authors:  J Bruix; A Castells; J Bosch; F Feu; J Fuster; J C Garcia-Pagan; J Visa; C Bru; J Rodés
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

6.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

7.  Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion.

Authors:  K Uesaka; Y Nimura; M Nagino
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

8.  Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis.

Authors:  Enric Reverter; Annabel Blasi; Juan G Abraldes; Graciela Martínez-Palli; Susana Seijo; Fanny Turon; Annalisa Berzigotti; Jaume Balust; Jaume Bosch; Juan C García-Pagán
Journal:  Liver Int       Date:  2013-06-13       Impact factor: 5.828

9.  The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.

Authors:  Gilberto Silva-Junior; Anna Baiges; Fanny Turon; Ferran Torres; Virginia Hernández-Gea; Jaime Bosch; Juan Carlos García-Pagán
Journal:  Hepatology       Date:  2015-09-30       Impact factor: 17.425

10.  Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.

Authors:  Andrea Lisotti; Francesco Azzaroli; Federica Buonfiglioli; Marco Montagnani; Paolo Cecinato; Laura Turco; Claudio Calvanese; Patrizia Simoni; Massimo Guardigli; Rosario Arena; Alessandro Cucchetti; Antonio Colecchia; Davide Festi; Rita Golfieri; Giuseppe Mazzella
Journal:  Hepatology       Date:  2013-12-20       Impact factor: 17.425

View more
  2 in total

1.  Hepatic function assessment to predict post-hepatectomy liver failure: what can we trust? A systematic review.

Authors:  Federico Tomassini; Mariano C Giglio; Giuseppe De Simone; Roberto Montalti; Roberto I Troisi
Journal:  Updates Surg       Date:  2020-08-04

2.  The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.

Authors:  Lei Chen; Yanqiao Ren; Tao Sun; Yanyan Cao; Liangliang Yan; Weihua Zhang; Tao Ouyang; Chuansheng Zheng
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.